Table 9

Comparisons across time within the secondary outcome measures within the combined group

NBaseline3-Month follow-upComparisons
PercentilesPercentilesz Statisticp Value
LowerMdnUpperLowerMdnUpper
CDC CFS sore throat29003.500012.030−0.5670.571
CDC CFS swollen lymph nodes/glands31024013−0.7250.046
CDC CFS diarrhoea31024002−1.9960.046*
CDC CFS fatigue after exertion318152061216−2.3920.017*
CDC CFS muscle aches/pains312612169−1.9080.056
CDC CFS pain in joints3001.5008014−1.6800.093
CDC CFS fever30001000.720−1.3830.167
CDC CFS chills31026012.150−2.0490.040*
CDC CFS unrefreshing sleep31612164916−1.5130.130
CDC CFS sleeping problems311612249−1.7940.073
CDC CFS headaches31269136−2.8070.005**
CDC CFS memory problems312612139−1.4460.148
CDC CFS difficulty concentrating3128121612−1.8990.058
CDC CFS nausea31016026−0.8550.392
CDC CFS abdominal pain31016024−0.5980.550
CDC CFS sinus nasal symptoms31058014−2.4820.013*
CDC CFS shortness of breath30026014−0.9760.329
CDC CFS sensitivity to light31016014−0.7870.431
CDC CFS depression31026016−1.3040.192
MHLCS internal310.5560.6940.8610.6390.7500.889−1.7550.079
MHLCS chance310.2220.3330.3610.1670.3060.417−0.6720.501
MHLCS powerful others310.3330.3890.5000.3330.3890.500−0.5770.564
MHLCS doctors310.1110.1670.2220.0830.1390.500−1.3840.166
MHLCS other people310.1670.2500.2780.1940.2500.306−0.2130.831
  • *Significant at 0.05 level.

  • **Significant at 0.01 level.

  • ***Significant at 0.001 level.

  • CFS, chronic fatigue syndrome; Mdn, median; MHLCS, Multidimensional Health Locus of Control Scale.